What Is Metastatic Lung Cancer?

Table of Contents
View All
Table of Contents

Metastatic lung cancer is cancer that starts in the lungs and spreads (metastasizes) to other parts of the body, such as the liver, brain, or bones. It is the most advanced lung cancer stage and is sometimes referred to as a stage 4 cancer.

Although metastatic lung cancer is challenging to treat, newer drugs are increasing survival times and quality of life for people who are diagnosed with this advanced disease.

Doctor and patient discuss diagnosis

SDI Productions / E+ / Getty Images

Types of Metastatic Lung Cancer

There are numerous types of lung cancer. While they can all metastasize if not treated, some are more likely to do so than others.

Metastatic Lung Cancer Symptoms

Even after lung cancer reaches an advanced stage, the most common symptoms can be relatively subtle or easily mistaken for less serious medical issues. This is so much so that 57% of lung cancers have already metastasized by the time they're diagnosed.

The most common lung cancer symptoms include:

As lung cancer metastasizes, other symptoms can develop:

Cause and Sites of Spread

Distant lung cancer metastasis occurs when tumor cells break away from where they originally developed and travel to other parts of the body.

The most common sites of lung cancer metastasis are:

  • Other lung
  • Brain
  • Bones
  • Liver
  • Adrenal glands

The process usually begins with local metastasis: when the cancer cells invade tissues close to the primary site. From there they can enter nearby lymph nodes and blood vessels and travel beyond the affected lung via the lymphatic system or bloodstream.

Along the way, the cancer cells might leave the lymphatic vessels or blood vessels and settle into tissues where they continue to grow.

When cancer spreads, it retains the same name as the original (primary) cancer. For example, lung cancer that spreads to the liver is still called lung cancer, or lung cancer metastatic to the liver.

This is true even if cancer in one lung is found to have spread to the other lung. In that case, the secondary diagnosis would be primary lung cancer metastatic to another lung.


Metastatic lung cancer may be detected due to monitoring being done because of a localized lung cancer diagnosis or because symptoms of spread prompted someone to seek an evaluation. Less often, it may be caught during screening.

Lung cancer is diagnosed using a variety of methods. Once a diagnosis is confirmed, it is further defined by stage—a classification that describes how advanced it is and that helps direct treatment.

Exam and Testing

The following may be done to detect and stage lung cancer:


Regardless of whether or not someone is experiencing symptoms, the U.S. Preventive Services Task Force recommends that certain people be screened for lung cancer using CT once a year.

You fall into this group if you:

  • Are 50 to 80 years old
  • Have a 20 pack-year or more history of smoking
  • Currently smoke or have quit within the past 15 years
  • Are generally well enough to undergo treatment if lung cancer is diagnosed


Cancer is staged to describe the extent to which it has spread and, therefore, the severity of disease. The two most common lung cancers are staged using different systems.

Non-small cell lung cancer has four main stages: 0 to 4.

NSCLC is regarded as stage 4 when it has spread to the second lung, the fluid around the lung or heart, or other distant body areas. 

There are two degrees of stage 4 metastatic NSCLC: stages 4a and 4b.

Stage 4a NSCLC
  • Spread to lymph nodes and/or other parts of the body (within the chest and/or an area outside of it)

  • Separate nodule(s) in the opposite lung

  • Tumor with nodules or cancerous fluid build-up in tissues lining the lungs or heart

  • Single metastasis in an organ or lymph node outside the chest

Stage 4b NSCLC
  • Spread is outside of the chest

  • Spread is to more than one place in a single organ or to more than one organ

SCLC is more commonly classified according to two stages:

  • Limited-stage SCLC: Cancer is present on only one side of the chest. Treatment can be with a single radiation field. In most circumstances, the cancer is only in one lung, but it might have reached the lymph nodes on the same side as that lung.
  • Extensive-stage SCLC (metastatic lung cancer): Cancer has spread widely throughout a single lung or it may have spread to the second lung, lymph nodes far from the tumor, or other parts of the body (including the fluid around the lung).

Lung Cancer Doctor Discussion Guide

Get our printable guide for your next doctor's appointment to help you ask the right questions.

Doctor Discussion Guide Man


Unfortunately, metastatic lung cancer is not easily treated. At stage 4, the tumor is no longer confined to a separate discreet area and it may be affecting organs and systems in the body other than the lungs.

For these reasons, treatment often is focused on palliative care—relieving symptoms, improving quality of life, and extending life—rather than attempting to cure cancer.

Palliative care takes into account not only someone's physical needs, but their psychological, spiritual, and social needs as well.

Options for NSCLC

The approach to treating stage 4 NSCLC may differ somewhat from that for stage 4 SCLC.

  • Gene mutation testing will often be performed before treatment. If specific gene mutations are identified, then targeted drug therapy will often be the first treatment line.
  • Also, tumor cells may be tested for the PD-L1 protein. If higher levels of this protein are found, then the cancer is more likely to respond to specific immunotherapy drugs.

Additional treatment options may include surgery, chemotherapy, radiation, or a combination of all three. Treatment will be further refined based on specific locations of metastases and effects of the tumor.

For example, if there is fluid in the tissues that line the heart or lungs (pericardial or plerual effusion), it may need to be removed. If there is a single brain metastasis, it might be treated with surgery and radiation.

In May 2020, the Food and Drug Administration approved Tabrecta (capmatinib) for adults diagnosed with aggressive stage 4 NSCLC that has spread to other parts of the body and whose gene testing shows MET Exon 14 skipping mutations. It can be prescribed as a first-line treatment for them as well as previously-treated patients.

Options for SCLC

SCLC has spread too far for surgery or radiation therapy to be successful as an initial treatment.

As such, chemotherapy and immunotherapy are used in the first-line treatment of extensive-stage SCLC. The combination of these two treatments is designed to shrink cancer, alleviate symptoms, and help you live longer.

If cancer responds to this, then radiation therapy might also be introduced. The goal of radiation is to help prolong life; radiation might also be considered to prevent cancer progression in the brain.

One of the key differences between NSCLC and SCLC is that SCLC is less responsive to many targeted drugs and immunotherapies. Research has identified that new therapeutic treatments have not significantly improved SCLC patient survival.

Immunotherapy, when combined with an anti-angiogenic agent, chemotherapy, or radiation, is thought to be the most promising SCLC treatment that has emerged in recent years.


The prognosis for metastatic lung cancer typically is measured in terms of survival rates. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and publishes detailed information about cancer incidence and survival in the United States.

The SEER database tracks five-year relative survival rates for NSCLC and SCLC. The five-year survival rate is the percentage of people who are expected to be alive five years after diagnosis. 

The SEER program categorizes data and survival estimates into three stages of lung and bronchus cancer:

  • Localized: Confined to the primary site
  • Regional: Spread to regional lymph nodes
  • Distant: Spread to other parts of the body

Please note that these are broad estimates and may not apply to your particular situation.

5-Year Relative Survival by Lung/Bronchus Cancer Stage at Diagnosis
Extent of Spread % Cases   Relative 5-Year Survival Rate
Localized  18% 59.8%
Regional   22% 32.9%
Distant  56% 6.3%

United States data; unstaged cases not included

Survival estimates have limitations, though. They reflect the entire population of people with lung cancer, regardless of age, health, cancer grade, or cancer type.

Cancer survival estimates can give a general idea about the survival rate of most people in your situation. However, they can't tell you your chances of curing your cancer or achieving remission as an individual.


During treatment, your healthcare provider, medical team, family, and friends can help you cope with metastatic lung cancer lifestyle changes, symptoms, and treatment side effects.

Reach out to them for help and emotional support and also consider these measures:

  • Learn: Get information about the disease, metastasis, staging, and treatments. Some people find that increasing their knowledge in these areas helps them face what's ahead. Ask your medical team as many questions as you need to.
  • Talk: Get a referral to a healthcare professional who you can talk to about your worries, emotions, and situation. They will be able to help you with coping strategies, psychological support, and lifestyle changes.
  • Take time out: Living with and managing cancer can be overwhelming and stressful. For your physical and mental health, be sure to schedule some downtime to do something that helps you relax.
  • Find a support network: Sometimes it helps to speak to other people who have been through or are in the same cancer stage as you. Ask your healthcare provider about local support groups that you could attend, or seek out online support or social media groups.
  • Focus on things you enjoy: Give yourself time to do something that makes you happy. Plan your activities for times of the day where you have the most energy and not much else to do.

If you are worried about how your family is coping with your diagnosis, encourage them to seek help too. There are in-person and online support groups for family members and caregivers just like there are for patients.

A Word From Verywell

The reality of metastatic lung cancer is a lot to process. But remember that advances in treatment have increased life expectancy. Survival rates are improving year by year, and death rates from lung and bronchus cancers have been improving 3.6% on average each year since 2009.

There are also many ongoing clinical trials. These studies give participants a chance to try the newest treatments. If you have been diagnosed with metastatic lung cancer and want to know how to be considered for a clinical trial, speak with your medical team about your options.

18 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Johns Hopkins Medicine. Lung cancer types.

  2. American Cancer Society. What is lung cancer?

  3. American Cancer Society. What are lung carcinoid tumors?

  4. Taşçı EŞ, Akın G, Öneç B, Eşbah O. Malignant pleural mesothelioma with rarely seen metastasesJ Oncol Sci. 2017;3(3):133-134. doi:10.1016/j.jons.2017.11.003

  5. National Cancer Institute. Cancer stat facts: Lung and bronchus cancer.

  6. American Cancer Society. Signs and symptoms of lung cancer.

  7. National Cancer Institute. Metastatic cancer: When cancer spreads.

  8. Cingam SR, Mukkamalla SKR, Karanchi H. Adrenal metastasis. StatPearls.

  9. American Society of Clinical Oncology. What is metastasis? 

  10. American Cancer Society. Tests for lung cancer.

  11. U.S. Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation StatementJAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117

  12. American Cancer Society. Small cell lung cancer stages. 

  13. American Cancer Society. Non-small cell lung cancer treatment.

  14. U.S. Food & Drug Administration. FDA approves first targeted therapy to treat aggressive form of lung cancer. 

  15. American Cancer Society. Treatment choices for small cell lung cancer, by stage. 

  16. Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39-50. doi:10.3978/j.issn.2218-6751.2016.01.03

  17. Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutationsExpert Rev Respir Med. 2020;14(2):125-136. doi:10.1080/17476348.2020.1701439

  18. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). 

By Helen Massy
Helen Massy, BSc, is a freelance medical and health writer with over a decade of experience working in the UK National Health Service as a physiotherapist and clinical specialist for respiratory disease.